ForwardVue Pharma

Executive Summary

ForwardVue Pharma is a preclinical-stage biotechnology company developing a VEGF-independent drug delivery platform for retinal diseases, targeting the ORAI1 channel. Founded in 2020 and headquartered in San Diego, the company aims to reduce treatment burden for conditions like diabetic retinopathy and age-related macular degeneration. Its lead program offers potential for durable therapeutic effects with less frequent dosing compared to current anti-VEGF therapies. As a private, early-stage company, ForwardVue has no disclosed funding rounds or valuation. The platform's novelty addresses a significant unmet need in ophthalmology, but preclinical validation and clinical translation remain key risks.

Upcoming Catalysts (preview)

• Q2 2027IND Submission for Lead ORAI1 Program30% success
• Q4 2026Initial Preclinical Efficacy Data Publication60% success
• Q4 2027Partnership or Licensing Deal with Larger Pharma40% success